COMMUNIQUÉS West-GlobeNewswire

eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
09/04/2024
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the [...]
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
09/04/2024
BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight [...]
Jaya Biosciences Presents New Paradigm for the Treatment of Alzheimer’s Disease at the 23ʳᵈ Annual Needham Virtual Healthcare Conference
09/04/2024
- Data presented highlight the potential utility of targeting lysosomal genes to treat neurodegenerative diseases, including Alzheimer’s - SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Jaya Biosciences [...]
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
09/04/2024
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior treatments in Bria-IMT™ [...]
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
09/04/2024
Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver [...]
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
09/04/2024
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet [...]
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
09/04/2024
Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network CONSHOHOCKEN, Pa., April [...]
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
09/04/2024
Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic [...]
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
09/04/2024
HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based [...]
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
09/04/2024
TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
09/04/2024
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today [...]
Vanqua Bio Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating VQ-101, its Small Molecule GCase Activator for GBA-Parkinson’s Disease and Related Disorders
09/04/2024
- VQ-101 is a potent allosteric activator of glucocerebrosidase (GCase) - The Phase 1 program aims to demonstrate VQ-101’s pharmacodynamic effects in healthy volunteers and Parkinson’s patients CHICAGO, April 09, 2024 ( [...]
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
09/04/2024
BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and [...]
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
09/04/2024
First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults LITTLETON, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: [...]
Emerging Markets Report: Follow the Leader
09/04/2024
Nvidia Defines Market Appetite for Healthcare and A.I. for HEALWELL An Emerging Markets Sponsored Commentary ORLANDO, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- For some time now the market has been in love with Nvidia ( [...]
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
09/04/2024
MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardless of underlying resistance mechanism Validation of novel translational assay enables detection [...]
Treace to Report First Quarter 2024 Financial Results
09/04/2024
Company to Host Conference Call on Tuesday, May 7, 2024 at 4:30 pm ET PONTE VEDRA, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical [...]
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
09/04/2024
Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates nominating a clinical candidate within the first year of the [...]
LSL Pharma Group Announces its Participation in the "2024 Bloom Burton & Co. Healthcare Investor Conference "
09/04/2024
BOUCHERVILLE, Quebec, , April 09, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC (TSXV: LSL) (the " Company " or " LSL Pharma "), a Canadian integrated pharmaceutical company, announced today that it will participate in [...]

Pages